- Home
- MCRB vs LODE Comparison
MCRB vs LODE Comparison
Compare MCRB & LODE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- LODE
- Stock Information
- Founded
- MCRB 2010
- LODE 2008
- Country
- MCRB United States
- LODE United States
- Employees
- MCRB N/A
- LODE N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- LODE Major Chemicals
- Sector
- MCRB Health Care
- LODE Industrials
- Exchange
- MCRB Nasdaq
- LODE Nasdaq
- Market Cap
- MCRB 144.6M
- LODE 168.0M
- IPO Year
- MCRB 2015
- LODE N/A
- Fundamental
- Price
- MCRB $17.75
- LODE $2.97
- Analyst Decision
- MCRB Hold
- LODE Hold
- Analyst Count
- MCRB 4
- LODE 1
- Target Price
- MCRB $14.33
- LODE $4.00
- AVG Volume (30 Days)
- MCRB 101.5K
- LODE 1.6M
- Earning Date
- MCRB 11-12-2025
- LODE 10-30-2025
- Dividend Yield
- MCRB N/A
- LODE N/A
- EPS Growth
- MCRB N/A
- LODE N/A
- EPS
- MCRB 10.22
- LODE N/A
- Revenue
- MCRB N/A
- LODE $3,280,749.00
- Revenue This Year
- MCRB N/A
- LODE $7.65
- Revenue Next Year
- MCRB N/A
- LODE $1,093.72
- P/E Ratio
- MCRB $1.74
- LODE N/A
- Revenue Growth
- MCRB N/A
- LODE 58.55
- 52 Week Low
- MCRB $6.53
- LODE $1.67
- 52 Week High
- MCRB $24.67
- LODE $10.10
- Technical
- Relative Strength Index (RSI)
- MCRB 42.40
- LODE 40.86
- Support Level
- MCRB $17.63
- LODE $3.41
- Resistance Level
- MCRB $19.30
- LODE $4.75
- Average True Range (ATR)
- MCRB 1.12
- LODE 0.36
- MACD
- MCRB -0.29
- LODE -0.12
- Stochastic Oscillator
- MCRB 5.42
- LODE 1.92
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.